用于治疗选择的分子分析：美国国立癌症研究所（NCI）MATCH计划。 - Suppr

Suppr

超能文献

Molecular analysis for therapy choice: NCI MATCH.

作者信息

Conley Barbara A, Doroshow James H

机构信息

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.

出版信息

Semin Oncol. 2014 Jun;41(3):297-9. doi: 10.1053/j.seminoncol.2014.05.002. Epub 2014 May 22.

DOI:10.1053/j.seminoncol.2014.05.002

PMID:25023344

Abstract

摘要

相似文献

Molecular analysis for therapy choice: NCI MATCH.

Semin Oncol. 2014 Jun;41(3):297-9. doi: 10.1053/j.seminoncol.2014.05.002. Epub 2014 May 22.

[Molecular genetic tumor markers and their analysis for diagnosis and therapy of cancer patients].

Klin Med (Mosk). 1999;77(11):4-9.

Biology-driven phase II trials: what is the optimal model for molecular selection?

J Clin Oncol. 2011 Apr 1;29(10):1236-8. doi: 10.1200/JCO.2010.31.6877. Epub 2011 Feb 22.

Personalized-medicine trials on the rise.

J Natl Cancer Inst. 2012 Oct 3;104(19):1425-6. doi: 10.1093/jnci/djs432. Epub 2012 Sep 24.

3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice.

Expert Rev Mol Diagn. 2004 Jul;4(4):431-3. doi: 10.1586/14737159.4.4.431.

Assessing cancer with a blood draw.

J Natl Cancer Inst. 2012 Dec 5;104(23):1774-5. doi: 10.1093/jnci/djs495.

[Biomarker for molecular targeting therapy against renal cell carcinoma].

Gan To Kagaku Ryoho. 2012 Jan;39(1):39-42.

Combining targeted drugs to stop resistant tumors.

Science. 2011 Mar 25;331(6024):1542-5. doi: 10.1126/science.331.6024.1542.

Somatic alterations as the basis for resistance to targeted therapies.

J Pathol. 2014 Jan;232(2):244-54. doi: 10.1002/path.4278.

Biomarkers as molecular targets of drug interventions.

Semin Oncol Nurs. 2012 May;28(2):109-15. doi: 10.1016/j.soncn.2012.03.004.

引用本文的文献

A Concordance Study Among 26 NGS Laboratories Participating in the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) Clinical Trial.

Clin Cancer Res. 2025 Jun 4. doi: 10.1158/1078-0432.CCR-24-2188.

Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.

JCO Precis Oncol. 2025 Feb;9:e2400451. doi: 10.1200/PO-24-00451. Epub 2025 Feb 6.

The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of individuals with metastatic breast cancer.

Breast Cancer Res Treat. 2025 Apr;210(3):551-562. doi: 10.1007/s10549-024-07591-5. Epub 2025 Jan 27.

[The collaborative project "Personalized medicine for oncology" (PM4Onco) as part of the Medical Informatics Initiative (MII)].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2024 Jun;67(6):668-675. doi: 10.1007/s00103-024-03886-6. Epub 2024 May 13.

Unlocking the Potential: A Systematic Review of Master Protocol in Pediatrics.

Ther Innov Regul Sci. 2024 Jul;58(4):634-644. doi: 10.1007/s43441-024-00656-z. Epub 2024 Apr 23.

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.

Clin Cancer Res. 2024 Apr 1;30(7):1273-1280. doi: 10.1158/1078-0432.CCR-23-0633.

Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.

Clin Cancer Res. 2024 Feb 16;30(4):786-792. doi: 10.1158/1078-0432.CCR-23-0983.

Molecular tumour boards - current and future considerations for precision oncology.

Nat Rev Clin Oncol. 2023 Dec;20(12):843-863. doi: 10.1038/s41571-023-00824-4. Epub 2023 Oct 16.

Functional precision oncology using patient-derived assays: bridging genotype and phenotype.

Nat Rev Clin Oncol. 2023 May;20(5):305-317. doi: 10.1038/s41571-023-00745-2. Epub 2023 Mar 13.

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).

Clin Cancer Res. 2023 Apr 14;29(8):1412-1422. doi: 10.1158/1078-0432.CCR-22-3334.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验